Biomedical subjects

J A Bernstein

Publications and source records attributed to J A Bernstein.

40 records · Page 3Linked to original sources

PubMedDate not supplied

Are high-dose toxic exposures always associated with reactive airways dysfunction syndrome (RADS)?

Bottling plant workers were evaluated for respiratory symptoms following an accidental exposure to a chlorine dioxide aerosol. Six exposed employees underwent medical and occupational histories, skin testing to common allergens, spirometry before and after use of bronchodilators, and methacholine challenge. The reported exposure to chlorine dioxide ranged from 30 min to 12 hr. Physical examinations were all normal. Four workers had positive prick skin tests to common aeroallergens. None of the workers demonstrated significant changes in forced expiratory volume in 1 sec following use of bronchodilators, and none experienced methacholine hyperresponsiveness. These cases suggest that the occurrence of reactive airways dysfunction syndrome is unpredictable and may not always occur in heavily exposed individuals.

Adult↗

PubMedDate not supplied

The mast cell: a comprehensive, updated review.

The mast cell has been suspected of playing an important clinical role for over a century. Improved techniques to isolate and purify homogeneous mast cell populations have made it easier to study mast cell activation, secretion, heterogeneity, and differentiation in several animal models including man. Despite the many laboratory accomplishments made which better characterize the mast cell, there is still a paucity of information that can be practically applied to clinical situations. This review will concentrate on events leading up to the recent advances made in specific areas of mast cell research.

Animals↗

PubMedDate not supplied

Chronic cutaneous bacterial hypersensitivity dermopathy: a second case and six year evaluation of the first case.

A case we described and reported 6 years ago as chronic cutaneous granulomatous dermopathy was believed due to bacterial hypersensitivity. We now report a second case with similar features of chronic recurrent indolent inflammatory skin lesions, nondiagnostic skin biopsies, and failure to respond to antibiotics. In the absence of another diagnosis and because of the remarkably similar appearance to the first case, we initiated a therapeutic trial with corticosteroids, which induced a remission. The initial case has now been observed for 6 years, and the patient remains in remission on 5 mg of prednisone on alternate days. The second case was considered consistent with bacterial allergy because of IgG and IgE antibodies against common cutaneous bacteria. As there were no granulomas in the current patient's skin lesions, a new designation, chronic cutaneous bacterial hypersensitivity, has been assigned. The differential diagnosis and criteria for this clinical entity are discussed. Either a remission from prednisone or control with low-dose prednisone may be achieved in this dermopathy, which is both disfiguring and frightening to patients.

Adult↗

PubMedDate not supplied

Clinical benefits of switching to an inhaled corticosteroid extrafine aerosol; a case series.

Hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol is the first in a new generation of inhaled corticosteroid (ICS) formulations that have an improved deposition profile in comparison with conventional ICS preparations. This reformulation offers potential benefits to patients with asthma in terms of improved symptom control and reduced oropharyngeal adverse effects, such as dysphonia and candidiasis. This article presents four cases that illustrate the clinical benefits that can be obtained following a switch from conventional ICS preparations to treatment with HFA-BDP extrafine aerosol. The patients described were experiencing significant exacerbations of their asthma and increasing asthma symptoms and/or oropharyngeal adverse effects during treatment with conventional ICS preparations. On switching to HFA-BDP extrafine aerosol, the patients experienced an improvement in their asthma control and resolution of any oropharyngeal adverse effects.

Administration, Inhalation↗